Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

Yaron Tomer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e3b1f380-8c61-11ed-9474-c3e3b839843d.jpg

First Name

Yaron

Last Name

Tomer

NPI

1982662334

Faculty ID

14884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yaron Tomer is the Marilyn and Stanley M. Katz Dean at Albert Einstein College of Medicine and Chief Academic Officer at Montefiore Medicine.</p>
<p>He received his M.D. degree magna cum laude from the Sackler School of Medicine of Tel Aviv University and trained in Internal Medicine at Sheba Medical Center, Israel, and in Endocrinology at the Icahn School of Medicine at Mount Sinai in New York. Prior to joining Montefiore Einstein in March 2016, he was Chief of the Division of Endocrinology, Diabetes, and Bone Disease at Mount Sinai.</p>
<p>Dr. Tomer has served on the editorial boards of <em>Endocrinology </em>and <em>The Journal of Clinical Endocrinology and Metabolism</em>, among others. He is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians. Dr. Tomer is the recipient of several prestigious awards, including the American Thyroid Association&rsquo;s Sidney H. Ingbar Distinguished Lectureship Award, as well as its Van Meter Award.</p>
<h3>Research</h3>
<p>Dr. Tomer&rsquo;s research program focuses on the immunogenetic, epigenetic, and environmental mechanisms underlying thyroid autoimmunity, and type 1 diabetes, and on targeting these mechanisms in order to develop novel therapies. His group made several discoveries including identifying new genes and mechanisms underlying the strong association between type 1 diabetes and autoimmune thyroiditis; demonstrating that CD40 and thyroglobulin are major susceptibility genes for thyroid autoimmunity; identifying a unique amino acid variant in the peptide binding pocket of HLA-DR that is key for the development of thyroid autoimmunity; dissecting the epigenetic mechanisms by which polymorphisms in the thyroglobulin and TSHR genes interact with environmental agents (e.g. viruses) to trigger thyroid autoimmunity; and identifying a novel small molecule that can block antigen presentation in autoimmune thyroiditis.</p>
<h3>Current Projects</h3>
<ol role="list">
<li><strong>Genetic and epigenetic studies in thyroid autoimmunity</strong><br />The Tomer lab mapped several susceptibility genes for autoimmune thyroid diseases (AITD) including CD40, thyroglobulin, and TSHR. Recent data suggest that variants in regulatory regions of some of these genes interact epigenetically with environmental factors (e.g., viral infections) to trigger disease. Current studies are using epigenomic screening, including whole genome methylation studies and ChiP-seq analyses to study these genetic-epigenetic interactions.</li>
<li><strong>Epigenetic studies in type 1 diabetes</strong><br />Similar studies are utilizing epigenomic screening to analyze epigenetic interactions between known type 1 diabetes susceptibility genes and interferon alpha, a key cytokine secreted during viral infections.</li>
<li><strong>Translational studies in autoimmune thyroiditis (AITD) and type 1 diabetes</strong><br />The Tomer lab discovered that the presence of arginine at position beta-74 of the peptide binding pocket of HLA-DR is critical for the development of AITD. This discovery led to a translational project aimed at blocking thyroid antigen presentation to T-cells by the arginine beta-74 HLA-DR peptide binding pocket as a potential therapy for AITD. Recently, the Tomer lab identified a small molecule, Cepharanthine, that can block antigen presentation and suppress AITD in mouse models. Similar studies are performed in type 1 diabetes where the aim is to block the HLA-DQ8 peptide binding pocket from presenting insulin peptides to T-cells as a novel strategy to treat autoimmune diabetes.</li>
<li><strong>Genetic and functional analyses of autoimmune polyglandular syndrome (APS) type 3</strong><br />The co-occurrence of type 1 diabetes and autoimmune thyroiditis in the same individual is considered a variant of the APS type 3 syndrome. The Tomer lab discovered several new susceptibility genes for APS3. The lab is now analyzing the mechanisms by which these genes predispose to disease.</li>
<li><strong>The role of viruses in triggering autoimmune thyroiditis and type 1 diabetes</strong><br />Certain infections, such as hepatitis C, are associated with autoimmune thyroiditis and diabetes. Current studies are aimed at dissecting the mechanisms by which interferon alpha, the primary cytokine secreted during viral infections, can trigger autoimmune thyroiditis and diabetes in genetically susceptible individuals.</li>
</ol>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol role="list">
<li>Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, <span class="underline">Tomer Y</span>. Molecular amino acid signatures in the MHC class II peptide binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci USA 2008; 105: 14034-14039.</li>
<li>Jacobson EM, Yang H, Menconi F, Wang R, Osman R, Skrabanek L, Li CW, Fadlalla M, Gandhi A, Chaturvedi V, Smith EP, Schwemberger S, Osterburg A, Babcock GF, <span class="underline">Tomer Y</span>. Employing a recombinant HLA-DR3 expression system to dissect MHC II-thyroglobulin peptide dynamism: A genetic, biochemical, and reverse immunological perspective. J Biol Chem 2009; 284: 34231-34243.</li>
<li>Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, <span class="underline">Tomer Y</span>. Autoimmune thyroiditis and diabetes: Dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-1466.</li>
<li>Menconi F, Osman R, Monti MC, Greenberg DA, Concepcion ES, <strong>Tomer Y</strong>. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. Proc Natl Acad Sci USA 2010; 107: 16899-16903.</li>
<li>Menconi F, Huber A, Osman R, Concepcion E, Jacobson EM, Stefan M, David, CS, <span class="underline">Tomer Y</span>. Tg.2098 is a major human thyroglobulin T-cell epitope. J Autoimmun 2010; 35: 45-51.</li>
<li>Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Concepcion E, Fadlalla M, Ho K, <span class="underline">Tomer Y</span>. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286: 31168-31179.</li>
<li>Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, Latif R, Keddache M, Zhang W, <span class="underline">Tomer Y</span>. Genetically driven target tissue overexpression of CD40: A novel mechanism in autoimmune disease. J Immunol 2012; 189: 3043-3053.</li>
<li>Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, <span class="underline">Tomer Y</span>. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci USA 2014; 111: 12562-12567.</li>
<li><span class="underline">Tomer Y</span>, Dolan LM, Kahaly G, Divers J, D&rsquo;Agostino Jr. RB, Imperatore G, Dabelea D, Marcovina S, Black MH, Pihoker C, Hasham A, Hammerstad SS, Greenberg DA, Lotay V, Zhang W, Monti MC, Matheis N. Genome wide identification of new genes and pathways in patients with autoimmune thyroiditis and type 1 diabetes. J Autoimmun 2015; 60: 32-39.</li>
<li>Li CW, Menconi F, Osman R, Mezei M, Jacobson EM, Concepcion E, David CS, Kastrinsky DB, Ohlmeyer M, <strong>Tomer Y</strong>. Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis. J Biol Chem 2016; 291: 4079-4090.</li>
<li>Li CW, Osman R, Menconi F, Concepcion ES, <span class="underline">Tomer Y</span>. Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J Autoimmun 2017; 76: 1-9.</li>
<li>Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, <span class="underline">Tomer Y</span>. Interferon alpha triggers autoimmune thyroid diseases via lysosomal-dependent degradation of thyroglobulin. J Clin Endocrinol Metab 2018; 103: 3678-3687.</li>
<li>Stefan-Lifshitz, M, Karakose E, Cui L, Ettela A, Yi Z, Zhang W, <span class="underline">Tomer Y</span>. Epigenetic modulation of &beta;-cells by interferon-&alpha; via PNPT1-miR26a-TET2 triggers autoimmune diabetes. JCI Insight 2019; 4: e126663.</li>
<li>Li CW, Osman R, Menconi F, Concepcion E, <span class="underline">Tomer Y</span>. Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves&rsquo; disease. J Autoimmun 2020; 108: 102402.</li>
<li>Lombardi, A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, <span class="underline">Tomer Y</span>. Retro-inverso D-peptides as a novel targeted immunotherapy for type 1 diabetes. J Autoimmune 2020; 115: 102543.</li>
<li>Li CW, Sachidanandam R, Jayaprakash A, Yi Z, Zhang W, Stefan-Lifshitz M, Concepcion E, <span class="underline">Tomer Y</span>. Identification of new rare variants associated with familial autoimmune thyroid diseases by deep sequencing of linked loci. J Clin Endocrinol Metab 2021; 12: 691781.</li>
<li>Ye J, Stefan-Lifshitz M, <span class="underline">Tomer Y</span>. Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation. J Biol Chem 2021; 296: 100774.</li>
<li>Li CW, Osman R, Menconi F, Faustino LC, Kim K, Clarke OB, Hou H, <span class="underline">Tomer Y</span>. Cepharanthine blocks presentation of thyroid and islet peptides in a novel humanized autoimmune diabetes and thyroiditis mouse model. Front Immunol 2021; 12: 796552.</li>
</ol>

EMR ID

81697

Is Open Scheduling

Off

Oren M. Tepper

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/580a0ef0-35cf-11ed-8123-8ffce84a9f6a.jpg

First Name

Oren

Last Name

Tepper

NPI

1972707636

Faculty ID

13107

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Tepper is a board-certified plastic surgeon, offering a wide spectrum of plastic surgery procedures to patients, ranging from surgery of the face to breast and body. He is a leading figure in the field of reconstructive surgery and was an early adopter on the use of virtual planning and 3D printing in both plastic and reconstructive surgery. Dr. Tepper strives to offer patients comprehensive care and the latest techniques in aesthetic and reconstructive surgery</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Dr. Tepper's clinical focus is&nbsp;on a wide spectrum of plastic surgery procedures for patients, ranging from surgery of the face to the breast and body.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Tepper's research focus has been on&nbsp;3D imaging in plastic surgery, and stem cell therapy to reverse age-related damage. Dr. Tepper strives to offer patients comprehensive care and the latest techniques in aesthetic and reconstructive surgery.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

5518

Biography

<p>Dr. Oren Tepper is the Director of Aesthetic Surgery, Montefiore, and an Associate Professor of Plastic Surgery, Albert Einstein College of Medicine.&nbsp; He is a board-certified plastic surgeon, and offers a wide spectrum of plastic surgery procedures to patients, ranging from surgery of the face to breast and body.</p><p>Dr. Tepper is a leading figure in the field of plastic surgery and has been an invited speaker at various national and international meetings. He has authored of over fifty textbook chapters and journal articles. Dr. Tepper's early pioneering work on 3D imaging in plastic surgery, and stem cell therapy to reverse age-related damage, have earned him a number of awards from national plastic surgery organizations. Dr. Tepper strives to offer patients comprehensive care and the latest techniques in aesthetic and reconstructive surgery.</p><p>Dr. Tepper completed his plastic surgery training at the Institute of Reconstructive Plastic Surgery, NYU Langone Medical Center. He graduated among the top of his class at the New York University School of Medicine, and was elected to the prestigious Alpha Omega Alpha society, as well as the sole recipient of an award for excellence based on scholarship and character.</p>

Is Open Scheduling

Off

Vafa Tabatabaie

https://assets.montefioreeinstein.org/profiles/images/Tabatabaie_Vafa_MD_2x.jpg

First Name

Vafa

Last Name

Tabatabaie

NPI

1861789976

Faculty ID

13732

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti Medical University in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007, initially as a clinical observer and then as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine. She then completed her Endocrinology Fellowship in 2013 and joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p>
<p>Dr. Tabatabaie is the Clinical Director for Division of Endocrinology.&nbsp;She is also the Director of Fracture Liaison Services, a multi-disciplinary team of Endocrinologist, Geriatricians and Orthopedic Surgeons focused on secondary prevention of osteoporotic fractures. &nbsp;Dr Tabatabaie is one of the founding members of Transgender Interest Group at Montefiore/Einstein. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer. She has contributed to the field of endocrinology by writing journal articles, presenting posters at national endocrine meetings, and mentoring medical students, residents and fellows. In recognition of her contributions to medical education, she was accepted into Leo M Davidoff Society in 2019. She also received Department of Medicine's Humanism Award in 2018.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort</strong></p>
<p>Cancers,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2021 Mar 23;13(6):1464</span></p>
<p>&nbsp;</p>
<p><strong>Are We Responding Effectively to Bone Mineral Density Loss and Fracture Risk in People with Epilepsy?</strong></p>
<p>Epilepsia Open, 2020 Apr 14;5(2): 240-247</p>
<p>&nbsp;</p>
<p><strong>Changes in Bone Mineral Density During 5 Years of Adjuvant Treatment in Premenopausal Breast Cancer Patients</strong></p>
<p>Breast Cancer Research and Treatment, 2020 Feb 19</p>
<p>&nbsp;</p>
<p><strong>Treatment of Diabetic Ketoacidosis and The Weekend Effect at an Urban Tertiary-Care Center</strong></p>
<p>Endocrine Practice,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2020 Jun 2;26(6):634-641</span></p>
<p>&nbsp;</p>
<p><strong>Thyroid Storm Presenting as Psychosis</strong></p>
<p>Journal of Investigative Medicine High Impact Case Reports, May 2018</p>
<p>&nbsp;</p>
<p><strong>Medical Optimization of Lumbar Fusion in the Osteoporotic Patient</strong></p>
<p>Archives of Osteoporosis, 2018 March 14: 13 (1): 26</p>
<p>&nbsp;</p>
<p><strong>Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels</strong></p>
<p>Journal Of Clinical Endocrinology and Metabolism. 2016 Aug; 101 (8): 3096-104</p>
<p>&nbsp;</p>
<p><strong>Effects of Testosterone Treatment in Older Men</strong></p>
<p>New England Journal of Medicine, 2016 Feb 18: 374 (7): 611-24</p>
<p>&nbsp;</p>
<p><strong>Recruitment and Screening for the Testosterone Trials</strong></p>
<p>The Journals of Gerontology, 2015 Sep, 70(9): 1105-11</p>
<p>&nbsp;</p>
<p><strong>Association of Sex Hormones with Sexual Function, Vitality, and Physical Function of Symptomatic Older Men with Low Testosterone Levels at Baseline in the Testosterone Trials</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2015 Mar, 100(3):1146-55</p>
<p>&nbsp;</p>
<p><strong>Exceptional Longevity is Associated with Decreased Reproduction</strong></p>
<p>Aging, 2011 Dec, 3(12):1202-5</p>
<p>&nbsp;</p>
<p><strong>Influence of Age and Primary Tumor Size on the Risk for Residual/Recurrent Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2009 Jun; 31(6):782-8</p>
<p>&nbsp;</p>
<p><strong>Post-Challenge Hyperglycemia in Older Adults is Associated with Increased Cardiovascular Risk Profile</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2009 May, 94(5):1595-601</p>
<p>&nbsp;</p>
<p><strong>Prognostic Value of Postsurgical Stimulated Thyroglobulin Levels after Initial Radioactive Iodine Therapy in Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2008 Jun; 30(6):693-700</p>

EMR ID

5083

Biography

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007 as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine, and she completed the Endocrinology Fellowship Program in 2013. She joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p><p>Dr. Tabatabaie is Director of the Fracture Liaison Service at Montefiore Medical Center. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer.</p>

Visit Type ID

2499

Is Open Scheduling

On

Simona Stefan

https://assets.montefioreeinstein.org/profiles/images/physphoto/Stefan_Simona_MD_LC_420x504.jpg

First Name

Simona

Last Name

Stefan

NPI

1932524915

Faculty ID

16368

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

114470

Visit Type ID

2499

Is Open Scheduling

On

Zocdoc Link

Preeti Kishore

https://assets.montefioreeinstein.org/profiles/images/physphoto/Kishore_Preeti_MD_420x504.jpg

First Name

Preeti

Last Name

Kishore

NPI

1477634806

Faculty ID

9299

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p style="font-family: 'Times New Roman'; font-size: 12.0pt; margin: 0pt 0pt .0001pt 0pt;"><span style="font-size: 10.0pt; font-family: Arial;">Dr. Preeti Kishore is a Professor in the Division of Endocrinology.&nbsp;</span><span style="font-family: Arial; font-size: 13.3333px;"> She is the site director for the Einstein/Montefiore Endocrinology Fellowship Program at Jacobi Medical Center. As Chief of the Endocrinology Division at Jacobi she is responsible for the clinical endocrine inpatient and outpatient operations at Jacobi and North Central Bronx Hospitals.</span><span style="font-family: Arial; font-size: 13.3333px;"> She actively participates in the teaching of endocrinology fellows, internal medicine residents and Einstein medical students. Her education philosophy is to empower learners to drive their own educational goals/learning. She is interested in the use of diabetes technology to manage low health literacy patients with diabetes. She is also the Director of the Weight Management Program at Jacobi.</span></p>
<p style="font-family: 'Times New Roman'; font-size: 12.0pt; margin: 0pt 0pt .0001pt 0pt;"><span style="font-family: Arial; font-size: 10pt;">Her research interests have been in Type 2 Diabetes Mellitus and the Insulin resistance syndrome. She has investigated the pathogenic role of free fatty acids in various aspects of </span><span style="font-family: Arial; font-size: 13.3333px;">Type 2 Diabetes Mellitus</span><span style="font-family: Arial; font-size: 10pt;">, particularly the role they play in regulating &ldquo;glucose effectiveness&rdquo;. She is also interested in the role of adipose tissue inflammation in the pathogenesis of the metabolic syndrome and insulin resistance. As an extension to her interest in adipose inflammation, she has investigated the role of vitamin D deficiency in Type 2 diabetes and whether it may regulate adipose inflammation/fibrosis. </span></p>
<p style="font-family: 'Times New Roman'; font-size: 12.0pt; margin: 0pt 0pt .0001pt 0pt;"><span style="font-family: Arial; font-size: 10pt;">Dr. Kishore is </span><span style="font-family: Arial; font-size: 13.3333px;">a member of the Leo M Davidoff Society and a</span><span style="font-family: Arial; font-size: 10pt;"> recipient of the prestigious Henry Christian Award of the American Federation of Medical Research. She is also the recipient of several teaching/advising awards.&nbsp;</span></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Selected Publications

<p>Esterson YB, Carey M, Boucai L, Goyal A, Raghavan P, Zhang K, Mehta D, Feng D, Wu L, Kehlenbrink S, Koppaka S, Kishore P, Hawkins M.Central Regulation of Glucose Production May Be Impaired in Type 2 Diabetes. Diabetes. 2016 Sep;65(9):2569-79</p>
<p>Kishore P, Boucai L, Zhang K, Li W, Koppaka S, Kehlenbrink S, Schiwek A, Esterson YB, Mehta D, Bursheh S, Su Y, Gutierrez-Juarez R, Muzumdar R, Schwartz GJ, Hawkins M. Activation of K(ATP) channels suppresses glucose production in humans. J Clin Invest. 2011 Dec;121(12):4916-20</p>
<p>Kishore P, Li W, Tonelli J, Lee DE, Koppaka S, Zhang K, Lin Y, Kehlenbrink S, Scherer PE, Hawkins M. Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages. Sci Transl Med. 2010 Feb 24;2(20):20ra15.</p>

EMR ID

4182

Is Open Scheduling

Off

Evan S. Garfein

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/9f1bca60-849b-11ee-bbe8-d94b407b9399.jpg

First Name

Evan

Last Name

Garfein

NPI

1790943546

Faculty ID

11649

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Evan Garfein completed a medical degree from Columbia University&rsquo;s College of Physicians and Surgeons, and trained in general surgery at Brigham and Women&rsquo;s Hospital. Between general surgery and plastic surgery training, Dr. Garfein conducted research at Harvard Medical School, concentrating on the role of hematopoietic stem cells in wound healing. He completed a plastic surgery residency at the Harvard Combined Plastic Surgery Residency Program, serving as chief resident at Massachusetts General Hospital, Children&rsquo;s Hospital Boston, and the Brigham and Women&rsquo;s Hospital. He also completed a microsurgery fellowship at the Institute of Reconstructive Plastic Surgery at New York University.</p>
<p>In 2010, Dr. Garfein authored a new bill requiring hospitals to inform breast cancer patients of breast reconstruction options after mastectomy.</p>
<p>Dr. Garfein was named Chief of the Division of Plastic Surgery at Montefiore Einstein in February 2014.</p>
<p>Dr. Garfein&rsquo;s research interests include the disparity in rates of breast reconstruction, advanced radiographic planning in the design of free flaps and perforator flaps, and prefabrication of flaps for functional reconstruction of the face.</p>
<p>Dr. Garfein&rsquo;s clinical interests are in microsurgical and complex reconstruction, particularly breast, lower extremity, and head and neck reconstruction. He has significant experience with surgical treatment of hidradenitis suppurativa, and is also interested in aesthetic surgery, particularly of the face, breasts and abdomen.</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

<p>Dr. Garfein's clinical interests are in microsurgical and complex reconstruction. He has received advanced training in the use of perforator flaps to minimize donor-site morbidity. His major interests are in breast, lower extremity, and head and neck reconstruction. Dr. Garfein performs all methods of breast reconstruction, including the deep inferior epigastric artery perforator (DIEP) flap, transverse upper gracilis (TUG) flap, thoracodorsal artery perforator (TDAP) flap and superficial inferior epigastric artery (SIEA) flap. He has significant experience with free fibular osseocutaneous flaps for reconstruction of head and neck defects. He is also interested in aesthetic surgery, particularly of the face, breasts and abdomen.</p>

Research Focus

<p>Dr. Garfein's research interests include the disparity in rates of breast reconstruction, advanced radiographic planning in the design of free flaps and perforator flaps, and in prefabrication of flaps for functional reconstruction of the face.</p>

Elsevier Profile

EMR ID

5138

Biography

<p>In 2008, Dr. Garfein founded the <em><a href="body.cfm?id=1324">In It Together Foundation</a></em> at Montefiore Medical Center. The Foundation assists disadvantaged patients with daily needs after reconstructive surgery.</p><p>In 2012, Dr. Garfein created a program that delivers current health information via text messages to residents of the Bronx. The &ldquo;Bronx4Bronx&rdquo; text messaging program is available in English and Spanish.</p><p>Dr. Garfein received his medical degree from Columbia University&rsquo;s College of Physicians and Surgeons. He trained in general surgery at the Brigham and Women&rsquo;s Hospital in Boston. Between his general surgery and plastic surgery training, Dr. Garfein conducted research at Harvard Medical School, concentrating on the role of hematopoietic stem cells in wound healing. Dr. Garfein completed his plastic surgery residency at the Harvard Combined Plastic Surgery Residency Program, serving as chief resident at Massachusetts General Hospital, Children&rsquo;s Hospital Boston and the Brigham and Women&rsquo;s Hospital. He also completed a microsurgery fellowship at the Institute of Reconstructive Plastic Surgery at New York University.</p>

Is Open Scheduling

Off

Sandra Aleksic

https://assets.montefioreeinstein.org/profiles/images/physphoto/Aleksic_Sandra_MD_420x504.jpg

First Name

Sandra

Last Name

Aleksic

NPI

1265864409

Faculty ID

16275

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Calibri, sans-serif; text-align: justify;"><span style="font-family: Calibri, sans-serif;">Dr. Sandra Aleksic is an Assistant Professor in Department of Medicine, Division of Endocrinology and Geriatrics. She earned her medical degree from the University of Belgrade Faculty of Medicine in Serbia. She completed residency in internal medicine at Rutgers New Jersey Medical School and fellowship in endocrinology, diabetes and metabolism at Montefiore Medical Center/Albert Einstein College of Medicine. She earned a Master of Science in Clinical Research Methods through Einstein&rsquo;s Clinical Research Training Program. She is the recipient of a Career Development Award from the Einstein/Montefiore Institute for Clinical and Translational Research, Resnick Emerging Scholar in Aging Research Award and Paul B. Beeson Emerging Leaders Career Development Award in Aging.&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Calibri, sans-serif; text-align: justify;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Calibri, sans-serif; text-align: justify;">Dr. Aleksic&rsquo;s research aims to uncover metabolic and endocrine mechanisms underlying healthy aging and longevity. Specifically, her translational research is focused on neuroendocrine regulation of aging and the role of the hypothalamus in human aging. Her team utilizes novel MRI-based methods to assess hypothalamic microstructure in order to elucidate its role in neuroendocrine and metabolic disturbances that underlie unhealthy aging and development of age-related disease.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><strong><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">Selected Publications:</span></span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull;&nbsp;</span></span><span style="color: #212121; font-family: 'system-ui', -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Aleksic S,</strong> Desai D, Ye K, Duran S, Gao T, Crandall J, Atzmon G, Barzilai N, Milman S. Integrity of hypothalamic-pituitary-testicular axis in exceptional longevity. Aging Cell. 2022 Jun 29:e13656. doi: 10.1111/acel.13656. Epub ahead of print. PMID: 35770332.</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull; </span></span><span style="font-size: 11.0pt; font-family: 'Arial',sans-serif;">Kulkarni AS*, <strong>Aleksic S</strong>*, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization. Aging Cell. 2022 Apr;21(4):e13596. doi: 10.1111/acel.13596. Epub 2022 Mar 27. PMID: 35343051; PMCID: PMC9009114 <strong><span style="color: #212121; background: white;">(*equally contributed)</span></strong></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull;&nbsp;</span></span><span style="font-family: Calibri, sans-serif; font-size: 16px;">Lontchi-Yimagou E*, </span><strong style="font-family: Calibri, sans-serif; font-size: 16px;">Aleksic S*,</strong><span style="font-family: Calibri, sans-serif; font-size: 16px;">&nbsp;Hulkower R, et al. Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure.&nbsp;</span><em style="font-family: Calibri, sans-serif; font-size: 16px;">J Clin Endocrinol Metab</em><span style="font-family: Calibri, sans-serif; font-size: 16px;">. 2020;105(11):dgaa539. PMID: 32915987. </span><span style="font-size: 11.0pt; font-family: 'Arial',sans-serif;"><strong><span style="color: #212121; background: white;">(*equally contributed)</span></strong></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull; <strong>Aleksic S</strong>, Eisenberg R, Tsomos E, et al. Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and</span></span> posttransplantation<span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;"> diabetes: A single-center retrospective study. Diabetes Res Clin Pract. 2020 Jul;165:108221. PMCID: PMC7415727.</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&nbsp;</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull; Carey M, Lontchi-Yimagou E, Mitchell W, Reda S, Zhang K, Kehlenbrink S, Koppaka S, Maginley SR, <strong>Aleksic S</strong>, Bhansali S, Huffman DM, Hawkins M. Central KATP Channels Modulate Glucose Effectiveness in Humans and Rodents. Diabetes. 2020 Jun;69(6):1140-1148. PMCID: PMC7243288.</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&nbsp;</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull; Zhang WB*, <strong>Aleksic S*</strong>, Gao T, et al. Insulin-like Growth Factor-1 and IGF Binding Proteins Predict All-Cause Mortality and Morbidity in Older Adults. Cells. 2020 Jun 1;9(6). PMCID: PMC7349399. </span></span><span style="font-size: 11.0pt; font-family: 'Arial',sans-serif;"><strong><span style="color: #212121; background: white;">(*equally contributed)</span></strong></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&nbsp;</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull; Jotic A, Milicic T, Covickovic Sternic N, Kostic VS, Lalic K, Jeremic V, Mijailovic M, Lukic L, Rajkovic N, Civcic M, Macesic M, Seferovic JP, Stanarcic J, <strong>Aleksic S</strong>, Lalic NM. Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke. Int J Endocrinol. 2015;2015:934791. PMCID: PMC4452095.</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull; Milicic T, Jotic A, Markovic I, Lalic K, Jeremic V, Lukic L, Rajkovic N, Popadic D, Macesic M, Seferovic JP, <strong>Aleksic S</strong>, Stanarcic J, Civcic M, Lalic NM. High Risk First Degree Relatives of Type 1 Diabetics: An Association with Increases in CXCR3(+) T Memory Cells Reflecting an Enhanced Activity of Th1 Autoimmune Response. Int J Endocrinol. 2014;2014:589360. PMCID: PMC3979071.</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&nbsp;</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&bull; Jotic A, Covickovic Sternic N, Kostic VS, Lalic K, Milicic T, Mijailovic M, Lukic Lj, Civcic M, Colak E, Macesic M, Seferovic JP, <strong>Aleksic S</strong>, Lalic N. Type 2 Diabetic Patients with Ischemic Stroke: Decreased Insulin Sensitivity and Decreases in Antioxidant Enzyme Activity Are Related to Different Stroke Subtypes. Int J Endocrinol. 2013;2013:401609. PMCID: PMC3697295.</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">&nbsp;</span></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Calibri, sans-serif; text-align: justify;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Calibri, sans-serif; text-align: justify;"><span style="font-size: 12pt;">&nbsp;</span></p>

EMR ID

88114

Visit Type ID

2499

Is Open Scheduling

On

Zocdoc Link

Shivani Agarwal

https://assets.montefioreeinstein.org/profiles/images/physphoto/Agarwal_Shivani_MD_420x504.jpg

First Name

Shivani

Last Name

Agarwal

NPI

1104144708

Faculty ID

15871

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal"><span style="font-size: 10.5pt; line-height: 107%; font-family: 'Verdana',sans-serif; color: black;"><span style="caret-color: #000000; text-size-adjust: auto;">Dr. Shivani Agarwal, MD, MPH is a practicing adult endocrinologist, Associate Professor of Medicine-Endocrinology, Associate Director of the Fleischer Institute for Diabetes and Metabolism, Director of the Supporting Emerging Adults with Diabetes (</span><a style="color: #0078d7; text-size-adjust: auto;" title="https://www.montefiore.org/sead&quot; href="https://www.montefiore.org/sead">SEAD</a><span style="caret-color: #000000; text-size-adjust: auto;">) program, and Director of Type 1 Diabetes programs, and Director of the Pilot and Feasibility Program of the NY-CDTR at the Albert Einstein College of Medicine and Montefiore Medical Center. </span></span></p>
<p class="MsoNormal"><span style="font-size: 10.5pt; line-height: 107%; font-family: 'Verdana',sans-serif; color: black;"><span style="caret-color: #000000; text-size-adjust: auto;">Dr. Agarwal is also a health services researcher with funding from the NIH-NIDDK, JDRF, and Helmsley Charitable Trust. Her work focuses on the impact of social determinants of health on diabetes, type 1 diabetes technology, and tests new models of healthcare redesign to address unmet social, psychological, and medical needs. She has expertise in health service redesigns, clinical trials, mixed methods evaluation, human-centered design methodology, and quality improvement.</span></span></p>
<p style="font-variant-ligatures: normal; font-variant-caps: normal; orphans: 2; text-align: start; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; word-spacing: 0px;"><span style="font-size: 10.5pt; font-family: 'Verdana',sans-serif; color: black;">She serves on the American Diabetes Association Healthcare Disparities Committee, and the Endocrine Society&rsquo;s Innovative Models in Diabetes Care Task Force as well as the Advocacy and Public Outreach Core Committee (APOCC). Her work has been published in a number of peer-reviewed journals and book chapters. She has received several awards for her work by the American Diabetes Association, Helmsley Charitable Trust, and Type 1 Diabetes Exchange.</span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Agarwal's clinical focus has been on the treatment of type 1 and type 2 diabetes in patients aged 18 to 35 years old.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Agarwal&rsquo;s research concentrates on clinical and behavioral interventions in young adults with type 1 diabetes.

Elsevier Profile

Selected Publications

<p>https://www.ncbi.nlm.nih.gov/myncbi/shivani.agarwal.1/bibliography/publ…;
<p>https://www.thelancet.com/series/global-inequity-diabetes</p&gt;

EMR ID

15218

Biography

<p>Shivani Agarwal, MD, MPH, is Director of the <span class="comment-text">SEAD (<a href="sead">Supporting Emerging Adults with Diabetes</a>) program </span>at Montefiore and an Assistant Professor of Medicine at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2018, her clinical focus has been on the treatment of type 1 and type 2 diabetes in patients aged 18 to 35 years old.</p><p>In 2001, Dr. Agarwal received her Bachelor of Arts in Neuroscience at Wellesley College. From 2005 to 2010, she attended New York University School of Medicine where she received her Doctor of Medicine. During this time, Dr. Agarwal also attended Johns Hopkins Bloomberg School of Public Health pursuing her Master of Public Health degree, which she received in 2009.</p><p>Dr. Agarwal began her postgraduate training in 2010 with a yearlong internship in Internal Medicine at Columbia University College of Physicians and Surgeons. She continued to train at this institution and completed a residency in Internal Medicine in 2013. Following this, in 2015, Dr. Agarwal completed a fellowship in Endocrinology at the University of Pennsylvania, followed by a postdoctoral research fellowship in 2016.</p><p>Extending from her clinical focus, Dr. Agarwal&rsquo;s research concentrates on clinical and behavioral interventions in young adults with type 1 diabetes. Her work has been published in a number of peer-reviewed journals, abstracts, and books. She has received several awards by the Helmsley Charitable Trust for her research and is an active member of the Type 1 Diabetes Exchange and SEARCH for Diabetes in Youth Consortium. She was also awarded the University of Pennsylvania Edward Rose Faculty Teaching Award in 2018.</p><p>Dr. Agarwal is board certified in Internal Medicine and Adult Endocrinology by the American Board of Internal Medicine and is a member of numerous professional societies, including the American College of Physicians, the American Diabetes Association, and the Endocrine Society. She also serves several elected roles on diabetes task forces and advocacy committees with the American Diabetes Association and Endocrine Society.</p><style type="text/css">.loaderVisible{overflow:hidden}.loader{width:100%;height:100%;position:absolute;top:0;left:0;background:#fff;z-index:10001;display:flex;align-items:center;justify-content:center;-webkit-transition:transform .3s ease-in-out;-moz-transition:transform .3s ease-in-out;transition:transform .3s ease-in-out}.loader--hidding{transform:translate(0,100%)}.loader__content{max-width:940px;height:80px;display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row}.loader__progress{border-left:1px solid #DBDBDB;color:#707070;font-family:ProximaNova-Regular,Arial,sans-serif;display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;align-items:center;padding-left:35px}.loader__progress a{color:#2f609f;text-decoration:none;margin-left:5px}.loader__progress a:hover{text-decoration:underline}.loader__logo{padding-right:40px;align-items:center;display:-webkit-flex;display:flex}.loader__logo img{max-height:600px;max-width:600px}.loader__circle{width:47px;height:47px;margin-right:20px}</style><style type="text/css">@font-face{font-family: ProximaNova-Bold;src:url(nv/assets/fonts/ProximaNovaWebFont/webfonts/32FA6A_0_0.woff)format("woff");}@font-face{font-family: ProximaNova-BoldIt;src:url(nv/assets/fonts/ProximaNovaWebFont/webfonts/32FA6A_1_0.woff)format("woff");}@font-face{font-family: ProximaNova-Light;src:url(nv/assets/fonts/ProximaNovaWebFont/webfonts/32FA6A_2_0.woff)format("woff");}@font-face{font-family: ProximaNova-LightIt;src:url(nv/assets/fonts/ProximaNovaWebFont/webfonts/32FA6A_3_0.woff)format("woff");}@font-face{font-family: ProximaNova-Regular;src:url(nv/assets/fonts/ProximaNovaWebFont/webfonts/32FA6A_4_0.woff)format("woff");}@font-face{font-family: ProximaNova-RegularIt;src:url(nv/assets/fonts/ProximaNovaWebFont/webfonts/32FA6A_5_0.woff)format("woff");}@font-face{font-family: ProximaNova-Semibold;src:url(nv/assets/fonts/ProximaNovaWebFont/webfonts/32FA6A_6_0.woff)format("woff");}</style><style id="detectElementResize" type="text/css">@keyframes resizeanim { from { opacity: 0; } to { opacity: 0; } } .resize-triggers { animation: 1ms resizeanim; visibility: hidden; opacity: 0; } .resize-triggers, .resize-triggers &amp;gt; div, .contract-trigger:before { content: " "; display: block; position: absolute; top: 0; left: 0; height: 100%; width: 100%; overflow: hidden; z-index: -1; } .resize-triggers &amp;gt; div { background: #eee; overflow: auto; } .contract-trigger:before { width: 200%; height: 200%; }</style>

Is Open Scheduling

On

Smita B. Abraham

https://assets.montefioreeinstein.org/profiles/images/physphoto/Abraham_Smita_MD_420x504.jpg

First Name

Smita

Last Name

Abraham

NPI

1831180603

Faculty ID

16678

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

119007

Visit Type ID

2499

Is Open Scheduling

On